RCM
RCKT icon

Requisite Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Requisite Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,000
Closed -$148K – 222
2018
Q4 		$148K Buy
+10,000
New +$166K 0.06% 55

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Requisite Capital Management's RCKT Position: Q1 2019 in Review

Requisite Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2019, closing a stake of 10,000 shares — an estimated $148K sold.

Requisite Capital Management first reported a position in RCKT in Q4 2018 and held it in 1 quarter. The position peaked at $148K in Q4 2018. 81 funds tracked by Wall St. Rank hold RCKT as of Q1 2019.

  • Requisite Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Requisite Capital Management sold 10,000 Rocket Pharmaceuticals shares in Q1 2019, an estimated $148K.
  • Requisite Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Requisite Capital Management's Rocket Pharmaceuticals position peaked at $148K in Q4 2018.
  • 81 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2019.

Based on Requisite Capital Management's 13F filing for Q1 2019, filed 15 May 2019.